Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05380349 · ClinicalTrials.gov registry record · Early Phase 1
Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma
A Early Phase 1 study of Newly Diagnosed Glioblastoma, sponsored by Swedish Medical Center.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT05380349: Recruiting Early Phase 1 study of Newly Diagnosed Glioblastoma, sponsored by Swedish Medical Center.
NCT05380349 is a Early Phase 1 study of Newly Diagnosed Glioblastoma that is actively recruiting participants, run by Swedish Medical Center. The registered enrollment target is 10 participants, below the 87-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05380349, a Early Phase 1 study of Newly Diagnosed Glioblastoma, is actively recruiting participants, sponsored by Swedish Medical Center.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
Primary Outcome
incidence of treatment-related AEs, laboratory abnormalities, and SAEs as assessed by CTCAE version 5.0
Conditions Studied
Interventions
- DRUG combinations of up to 3 FDA approved drugs from a panel of compounds
Study Locations (1)
Washington
- Swedish Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2024-04-19 |
| Est. Completion | 2027-12 |
| Phase | Early Phase 1 |
What NCT05380349 shows while recruiting
NCT05380349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 87-participant average among 4 other Newly Diagnosed Glioblastoma trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Newly Diagnosed Glioblastoma appearing as the primary indexed condition, and to 1 intervention - of which combinations of up to 3 FDA approved drugs from a panel of compounds is the first listed.
NCT05380349 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT05380349 about?
NCT05380349 is a clinical study titled "Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma". Proposed treatment of subjects with newly diagnosed glioblastoma with novel personalized drug regimens identified to be effective in vitro using cancer stem cells derived from their individual tumors, alongside standard of care radiation and TMZ.
What is the current status of trial NCT05380349?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2024-04-19. Estimated completion is 2027-12.
What conditions does trial NCT05380349 study?
This clinical trial studies the following conditions: Newly Diagnosed Glioblastoma.
What interventions are being tested in trial NCT05380349?
The interventions under investigation include: combinations of up to 3 FDA approved drugs from a panel of compounds (DRUG).
Who is sponsoring clinical trial NCT05380349?
This trial is sponsored by Swedish Medical Center, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05380349 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Newly Diagnosed Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RECRUITING · Phase 2
-
Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab
RECRUITING · Phase 2
-
Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma
RECRUITING · Phase 2
-
Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI